These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 20010167

  • 1. Integrating novel therapies in the transplant paradigm.
    Harousseau JL.
    Cancer J; 2009; 15(6):479-84. PubMed ID: 20010167
    [Abstract] [Full Text] [Related]

  • 2. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A, Attal M, Roussel M.
    Clin Cancer Res; 2011 Mar 15; 17(6):1253-63. PubMed ID: 21411441
    [Abstract] [Full Text] [Related]

  • 3. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Kaufman JL, Nooka A, Vrana M, Gleason C, Heffner LT, Lonial S.
    Cancer; 2010 Jul 01; 116(13):3143-51. PubMed ID: 20564642
    [Abstract] [Full Text] [Related]

  • 4. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS, Min CK, Cho BS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Kim Y.
    Jpn J Clin Oncol; 2009 Jul 01; 39(7):449-55. PubMed ID: 19487425
    [Abstract] [Full Text] [Related]

  • 5. Advances in therapy of multiple myeloma.
    Bladé J, Rosiñol L.
    Curr Opin Oncol; 2008 Nov 01; 20(6):697-704. PubMed ID: 18841053
    [Abstract] [Full Text] [Related]

  • 6. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
    Palumbo A, Gay F, Falco P, Crippa C, Montefusco V, Patriarca F, Rossini F, Caltagirone S, Benevolo G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Giuliani N, Petrucci MT, Musto P, Liberati AM, Rossi G, Corradini P, Boccadoro M.
    J Clin Oncol; 2010 Feb 10; 28(5):800-7. PubMed ID: 20048187
    [Abstract] [Full Text] [Related]

  • 7. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec 10; 18(104):263-6. PubMed ID: 20025098
    [Abstract] [Full Text] [Related]

  • 8. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.
    Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM, Hulin C, Benboubker L, Fuzibet JG, Renaud M, Moreau P, Avet-Loiseau H.
    Haematologica; 2006 Nov 10; 91(11):1498-505. PubMed ID: 17043025
    [Abstract] [Full Text] [Related]

  • 9. Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.
    Sahebi F, Frankel PH, Farol L, Krishnan AY, Cai JL, Somlo G, Thomas SH, Reburiano E, Popplewell LL, Parker PM, Spielberger RT, Kogut NM, Karanes C, Htut M, Ruel C, Duarte L, Murata-Collins JL, Forman SJ.
    Biol Blood Marrow Transplant; 2012 Mar 10; 18(3):486-92. PubMed ID: 22198542
    [Abstract] [Full Text] [Related]

  • 10. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C, Gockerman JP, Diehl LF, de Castro CM, Moore JO, Long GD, Horwitz ME, Keogh G, Chute JP, Sullivan KM, Neuwirth R, Davis PH, Sutton LM, Anderson RD, Chao NJ, Rizzieri D.
    Biol Blood Marrow Transplant; 2010 Jan 10; 16(1):70-7. PubMed ID: 19733251
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
    Morgan G.
    Blood Rev; 2010 Nov 10; 24 Suppl 1():S27-32. PubMed ID: 21126634
    [Abstract] [Full Text] [Related]

  • 13. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
    Vogl DT, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, Tsai DE, Perl A, Loren AW, Goldstein SC, Nasta SD, Andreadis C, Mangan PA, Hummel K, Siegel DL, Glatstein E, Stadtmauer EA.
    Am J Hematol; 2007 Dec 10; 82(12):1071-5. PubMed ID: 17696204
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Novel agents for relapsed and/or refractory multiple myeloma.
    Thomas SK, Richards TA, Weber DM.
    Cancer J; 2009 Dec 10; 15(6):485-93. PubMed ID: 20010168
    [Abstract] [Full Text] [Related]

  • 17. Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma.
    Lonial S, Cavenagh J.
    Br J Haematol; 2009 Jun 10; 145(6):681-708. PubMed ID: 19344388
    [Abstract] [Full Text] [Related]

  • 18. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.
    Rosiñol L, Oriol A, Mateos MV, Sureda A, García-Sánchez P, Gutiérrez N, Alegre A, Lahuerta JJ, de la Rubia J, Herrero C, Liu X, Van de Velde H, San Miguel J, Bladé J.
    J Clin Oncol; 2007 Oct 01; 25(28):4452-8. PubMed ID: 17785704
    [Abstract] [Full Text] [Related]

  • 19. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
    Sonneveld P, Goldschmidt H, Rosiñol L, Bladé J, Lahuerta JJ, Cavo M, Tacchetti P, Zamagni E, Attal M, Lokhorst HM, Desai A, Cakana A, Liu K, van de Velde H, Esseltine DL, Moreau P.
    J Clin Oncol; 2013 Sep 10; 31(26):3279-87. PubMed ID: 23897961
    [Abstract] [Full Text] [Related]

  • 20. Induction therapy in multiple myeloma.
    Harousseau JL.
    Hematology Am Soc Hematol Educ Program; 2008 Sep 10; ():306-12. PubMed ID: 19074101
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.